Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
48
MREO Quote, Financials, Valuation and Earnings
Last price:
$2.03
Seasonality move
:
15.38%
Day range:
$1.90 - $2.06
52-week range:
$1.47 - $3.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
612.02x
P/B ratio:
6.69x
Volume:
11.6M
Avg. volume:
1.8M
1-year change:
-44.79%
Market cap:
$311.6M
Revenue:
--
EPS (TTM):
-$0.26
Analysts' Opinion
-
Consensus RatingMereo BioPharma Group Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.06, Mereo BioPharma Group Plc has an estimated upside of 260.02% from its current price of $1.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.97 representing 100% downside risk from its current price of $1.96.
Fair Value
-
According to the consensus of 6 analysts, Mereo BioPharma Group Plc has 260.02% upside to fair value with a price target of $7.06 per share.
MREO vs. S&P 500
-
Over the past 5 trading days, Mereo BioPharma Group Plc has overperformed the S&P 500 by 9.49% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Mereo BioPharma Group Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mereo BioPharma Group Plc has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mereo BioPharma Group Plc reported revenues of --.
Earnings Growth
-
Mereo BioPharma Group Plc has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Mereo BioPharma Group Plc reported earnings per share of -$0.04.
Enterprise value:
263.3M
EV / Invested capital:
5.60x
Price / LTM sales:
612.02x
EV / EBIT:
--
EV / Revenue:
520.54x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.98x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$471.7K
Return On Assets:
-59.61%
Net Income Margin (TTM):
-8240.36%
Return On Equity:
-70.81%
Return On Invested Capital:
-67.41%
Operating Margin:
-2099.88%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $505.9K | -- | -- | |
| Gross Profit | -- | -$817K | -$471.7K | -$284.9K | -- | |
| Operating Income | -- | -$38.1M | -$47.3M | -$9.5M | -$10.3M | |
| EBITDA | -- | -$43.4M | -$46.4M | -$9.2M | -$10.3M | |
| Diluted EPS | -- | -$0.25 | -$0.26 | -$0.10 | -$0.04 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $86.7M | $52.4M | |
| Total Assets | -- | -- | -- | $88.7M | $53.6M | |
| Current Liabilities | -- | -- | -- | $14.2M | $6M | |
| Total Liabilities | -- | -- | -- | $16.2M | $7M | |
| Total Equity | -- | -- | -- | $72.5M | $46.6M | |
| Total Debt | -- | -- | -- | $5.9M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$30.2M | -$32.7M | -$7.6M | -$7.3M | |
| Cash From Investing | -- | -$699K | -$17.2K | -$2.9K | $302.7K | |
| Cash From Financing | -- | $46.2M | $60.8K | -$401K | -$1.4K | |
| Free Cash Flow | -- | -$30.9M | -$33M | -$7.6M | -$7.3M | |
MREO
Sector
Market Cap
$311.6M
$28.4M
Price % of 52-Week High
49.75%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
0.33%
-1.32%
1-Year Price Total Return
-44.79%
-22.19%
Beta (5-Year)
0.376
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.83
200-day SMA
Sell
Level
$2.14
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$1.81
Relative Strength Index (RSI14)
Buy
Level
62.48
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-50
50-day SMA
Buy
Level
$1.92
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.5541)
Sell
CA Score
(Annual)
Level (-2.1685)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.2575)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Stock Forecast FAQ
In the current month, MREO has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MREO average analyst price target in the past 3 months is $7.06.
-
Where Will Mereo BioPharma Group Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mereo BioPharma Group Plc share price will rise to $7.06 per share over the next 12 months.
-
What Do Analysts Say About Mereo BioPharma Group Plc?
Analysts are divided on their view about Mereo BioPharma Group Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mereo BioPharma Group Plc is a Sell and believe this share price will drop from its current level to $4.97.
-
What Is Mereo BioPharma Group Plc's Price Target?
The price target for Mereo BioPharma Group Plc over the next 1-year time period is forecast to be $7.06 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MREO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mereo BioPharma Group Plc is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MREO?
You can purchase shares of Mereo BioPharma Group Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mereo BioPharma Group Plc shares.
-
What Is The Mereo BioPharma Group Plc Share Price Today?
Mereo BioPharma Group Plc was last trading at $2.03 per share. This represents the most recent stock quote for Mereo BioPharma Group Plc. Yesterday, Mereo BioPharma Group Plc closed at $1.96 per share.
-
How To Buy Mereo BioPharma Group Plc Stock Online?
In order to purchase Mereo BioPharma Group Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MREO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MREO
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
6.69x
1.84x
Price / LTM sales
612.02x
1.60x
Growth Metrics
MREO
Sector
Revenue growth
--
4.85%
Earnings growth
55.69%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.00
-$0.20
Profitability
MREO
Sector
Profitability FY 2024
-$1.1M
$3.6M
Return on invested capital
-67.41%
-30.98%
Return on assets
-59.61%
-27.62%
Return on equity
-70.81%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
25
Estimated Next Earnings Date
Feb
9
Balance Sheet
MREO
Sector
Total cash
$48.7M
$27.2M
Short term investments
--
$25.7M
Total assets
$76.4M
$79.9M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
